Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
Biohaven Ltd. (BHVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results • First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial und
How this was made
The 30-second read
Why it matters
Key tradable catalysts are the initiation of a pivotal Phase 3 for BHV-1300 in Graves’ disease, planned Phase 3 initiation for BHV-1400 in 2H 2026, and a stated pivotal readout timing for opakalim in 2H 2026.
Market read
Traders can update probability-weighted pipeline expectations and monitor the 2H 2026 milestone calendar implied by the filing.
What to watch
The excerpt emphasizes program milestones but provides limited detail on cash runway, dilution risk, and full financial metrics, which can cap upside if funding needs rise.
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
Second-quarter operating expenses and net loss declined materially from the prior-year period following program reprioritization and lower direct and preclinical spend, while the company advanced several clinical programs. The filing reports no revenue, continued net losses, $259,480 (Amounts in thousands) of notes payable, and key value-driving clinical readouts and pivotal-study initiations remain ahead in 2H 2026.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expensesGAAP | $100.8M | – | decrease of $83.6 million |
| General and administrative expensesGAAP | $24.1M | – | decrease of $3.2 million |
| Total operating expensesGAAP | $124.9M | – | – |
| Loss from operationsGAAP | −$124.9M | – | – |
| Other (expense) income, netGAAP | other expense, net of $12.0 million | – | decrease of $25.8 million |
| Loss before provision for income taxesGAAP | −$136.9M | – | – |
| Provision for income taxesGAAP | 391K | – | – |
| Net lossGAAP | $137.3M | – | – |
| Net loss per shareGAAP | $0.91 per share | – | – |
| Weighted average common shares outstanding, basic and dilutedother | 150,636,620 | – | – |
| Non-cash share-based compensation expenseGAAP | $12M | – | decrease of $1.1 million |
| Non-cash share-based compensation expense in general and administrative expensesGAAP | $7.2M | – | decrease of $0.5 million |
| Non-GAAP adjusted net lossnon-GAAP | $118.1M | – | – |
| Non-GAAP adjusted net loss per sharenon-GAAP | $0.78 per share | – | – |
| Six-month research and development expensesGAAP | $204.6M | – | – |
| Six-month general and administrative expensesGAAP | 50.69M | – | – |
| Six-month total operating expensesGAAP | 255.3M | – | – |
| Six-month loss from operationsGAAP | −255.3M | – | – |
| Six-month other (expense) income, netGAAP | −11.85M | – | – |
| Six-month loss before provision for income taxesGAAP | −267.2M | – | – |
| Six-month provision for income taxesGAAP | 663K | – | – |
| Six-month net lossGAAP | −$267.8M | – | – |
| Six-month net loss per share, basic and dilutedGAAP | $ (1.80) | – | – |
| Six-month weighted average common shares outstanding, basic and dilutedother | 149,134,255 | – | – |
| Six-month non-GAAP adjusted net lossnon-GAAP | −$220.4M | – | – |
| Six-month non-GAAP adjusted net loss per share, basic and dilutednon-GAAP | $ (1.48) | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
2H 2026 outlook
- NoteTopline results from the Phase 2/3 RISE3 trial in focal epilepsy are expected during 2H 2026.
- NoteTopline data expected during 2H 2026 for the Phase 2 study of taldefgrobep alfa in obesity.
- NoteBHV-1400: Pivotal study initiation in IgAN study targeted for 2H 2026.
- NoteNew data on BHV-1530 will be presented at the ESMO Congress 2026 in October 2026.
- NoteContinue enrolling patients in the ongoing Phase 3 study in Graves' disease following June 2026 study initiation.
What drove it
- R&D expenses decreased primarily because of decreases in direct program spend and preclinical spend in 2026 compared with the same period in the prior year.
- The decrease in direct program spend was largely due to strategic reprioritization of programs implemented in the fourth quarter of 2025 and one-time developmental milestones of $15.0 million for BHV-8000 and $10.0 million for BHV-1530 recorded during the three months ended June 30, 2025.
- G&A expenses declined primarily because of decreased legal costs and employee costs, including non-cash share based compensation expense.
- Other (expense) income, net declined primarily due to increased non-cash losses related to changes in fair value of notes payable liability under the NPA and gains recorded in the prior-year period for non-cash changes in fair value of forward contracts and derivative liabilities.
- The company initiated a pivotal Phase 3 study of BHV-1300 in Graves' disease and plans to initiate a pivotal Phase 3 study of BHV-1400 in IgAN in 2H 2026.
Concerns
- The company reported a GAAP net loss of $137.3 million for the three months ended June 30, 2026.
- The filing reports no revenue or commercial segment revenue.
- Notes payable were 259,480 (Amounts in thousands) as of June 30, 2026.
- Other expense, net was $12.0 million in the second quarter of 2026, versus other income, net of $13.8 million in the prior-year period.
- The pivotal readout for opakalim and topline obesity data are expected during 2H 2026, while BHV-1400 pivotal-study initiation is targeted for 2H 2026.
What to watch
- Topline results for the first Phase 2/3 opakalim study in focal epilepsy expected in 2H 2026.
- Topline data from the Phase 2 obesity study of taldefgrobep alfa expected during 2H 2026.
- Progress of enrollment in the randomized, double-blind, placebo-controlled Phase 3 BHV-1300 study in approximately 300 adults with Graves' hyperthyroidism.
- Initiation of the BHV-1400 pivotal study in IgAN targeted for 2H 2026.
- New BHV-1530 Phase 1 data scheduled for presentation at the ESMO Congress 2026 in October 2026.
Balance sheet and cash flow
- Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2026, totaled approximately $270.5 million.
- Cash and cash equivalents were $ 238,033 (Amounts in thousands) as of June 30, 2026, compared to $ 229,957 (Amounts in thousands) as of December 31, 2025.
- Marketable securities were 29,833 (Amounts in thousands) as of June 30, 2026, compared to 89,180 (Amounts in thousands) as of December 31, 2025.
- Notes payable were 259,480 (Amounts in thousands) as of June 30, 2026, compared to 238,900 (Amounts in thousands) as of December 31, 2025.
- Total assets were $ 370,739 (Amounts in thousands) as of June 30, 2026, compared to $ 451,447 (Amounts in thousands) as of December 31, 2025.
- Total liabilities were 358,517 (Amounts in thousands) as of June 30, 2026, compared to 399,375 (Amounts in thousands) as of December 31, 2025.
- Total shareholders' equity was 12,222 (Amounts in thousands) as of June 30, 2026, compared to 52,072 (Amounts in thousands) as of December 31, 2025.
Analysis
Biohaven remained a clinical-stage company in the second quarter, with the filing reporting no revenue and a GAAP net loss of $137.3 million, or $0.91 per share. The loss improved from $198.1 million, or $1.94 per share, in the same period of 2025. Non-GAAP adjusted net loss was $118.1 million, or $0.78 per share, compared with $166.4 million, or $1.63 per share. The non-GAAP measure excludes non-cash share-based compensation and changes in the fair value of derivative liabilities.
The main financial change was lower spending. R&D expense fell to $100.8 million from $184.4 million, and G&A expense declined to $24.1 million from $27.3 million. Management attributed the R&D reduction to lower direct program and preclinical spending, its fourth-quarter 2025 strategic program reprioritization, and prior-year one-time developmental milestones for BHV-8000 and BHV-1530. These reductions brought total operating expenses to $124,899 (Amounts in thousands), compared with $211,701 (Amounts in thousands) a year earlier.
Clinical execution is centered on the extracellular-degrader and neuroscience pipelines. Biohaven initiated a pivotal Phase 3 study of BHV-1300 in Graves' disease after Phase 1b data in which weekly 1000 mg subcutaneous administration achieved mean reductions of pathogenic TSHR-IgG1 autoantibodies of greater than 80% by week 12. It also reported that BHV-1400 achieved mean reductions of pathogenic Gd-IgA1 of greater than 60% within 48 hours and approximately 70% within the first month of dosing. The next major anticipated clinical events are opakalim focal-epilepsy results and taldefgrobep alfa obesity data in 2H 2026, as well as BHV-1400 pivotal-study initiation targeted for 2H 2026.
Liquidity and liabilities warrant attention alongside the clinical calendar. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $270.5 million as of June 30, 2026, while notes payable were 259,480 (Amounts in thousands). Other expense, net was $12.0 million, compared with other income, net of $13.8 million in the prior-year period, principally reflecting non-cash fair-value losses on the notes payable liability and prior-year derivative-related gains. The filing provides no financial revenue, margin, operating-expense, or tax-rate guidance, so the disclosed outlook is limited to development milestones.
Management, verbatim
What excites me most about Biohaven today is that we're no longer talking about scientific promise—we're watching new therapeutic approaches begin to work in patients.
Vlad Coric, M.D., Chairman and Chief Executive Officer
If these data continue to translate into larger studies, extracellular protein degradation has the potential to reshape how autoimmune diseases are treated.
Vlad Coric, M.D., Chairman and Chief Executive Officer
As we approach our pivotal readout later this year, we believe we have the opportunity to introduce an important new treatment option for patients who deserve both seizure control and the ability to fully participate in their everyday lives.
Vlad Coric, M.D., Chairman and Chief Executive Officer
Not in the filing
stated, not guessed- Revenue for the three months ended June 30, 2026 and prior-year comparison were not reported.
- Revenue segments and segment revenue comparisons were not reported.
- Gross profit and gross margin were not reported.
- Operating cash flow and free cash flow were not reported.
- Share repurchases, dividends, and other capital-return activity were not reported.
- Financial guidance for revenue, gross margin, operating expenses, and tax rate was not reported.
- A prior outlook section was not provided, so comparison of actual results with prior guidance is unavailable.
- Quarter-over-quarter comparisons for reported financial metrics were not reported.
- Tax rate was not reported.
- Restricted cash as a separate balance-sheet line item was not reported.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Biohaven’s 8-K (Item 2.02) reports Q2 2026 financial results and highlights pipeline progress across extracellular degraders, epilepsy therapy opakalim, and oncology ADC programs.
Ticker impact
Biohaven filed an 8-K with Q2 results and disclosed new clinical progress, including initiating a pivotal Phase 3 for BHV-1300 in Graves’ disease.
Near-term upside bias on risk-on biotech sentiment, with follow-through likely into the next major readouts (2H 2026) if market focuses on trial progression.
This is a primary SEC filing with specific program milestones, but it does not include financial guidance numbers in the provided excerpt, limiting certainty on earnings-driven repricing.
Market effects
Reinforces investor appetite for extracellular protein degrader platforms and ADC combinations, potentially supporting peer sentiment in autoimmune and oncology biotech.
Primarily US-listed biotech sentiment; limited direct regional spillover beyond biotech risk appetite.
ESMO October 2026 presentation and global trial execution can influence international biotech conference-driven expectations.
Counterpoint
Clinical biomarker and early safety signals may not translate into Phase 3 efficacy endpoints, so the market may over-discount early pharmacodynamic results.
Key entities
- issuerBiohaven Ltd.
NYSE-listed clinical-stage biopharmaceutical company filing an 8-K with Q2 results and pipeline milestones.
- drug_programBHV-1300
Extracellular protein degrader in Graves’ disease; pivotal Phase 3 initiated based on Phase 1b biomarker and safety data.
- drug_programBHV-1400
Extracellular degrader in IgA nephropathy; pivotal study expected to initiate in 2H 2026.
- drug_programopakalim
Selective Kv7.2/7.3 activator for epilepsy; pivotal readout on track for 2H 2026.
